扶正抗癌方联合CHOP方案治疗非霍奇金淋巴瘤的临床观察
|
摘要
目的:评价扶正抗癌方联合CHOP方案治疗中高度恶性NHL的疗效
方法:选取我校附院肿瘤科2005年6月至2007年6月住院部所收治的40例符合研究条件的各期NHL患者,依据其接受的治疗不同分为联合治疗组和单纯化疗组,各20例。两组均接受了2周期的CHOP化疗,其中联合化疗组于CHOP方案化疗前5天开始服用扶正抗癌150ml/tid,并一直坚持持续服药。观察两组化疗结束时,患者生活质量改善情况及毒副反应。
结果:联合治疗组和单纯化疗组相比其中医证候及其病情改善均有统计学意义(P＜0.05)。
结论:依据中医补脾益肾,填精补元理论配伍的扶正抗癌方联合CHOP方案治疗NHL,能够改善患者病情,稳定病灶,提高患者生活质量,且有显著疗效,值得临床推广。
Objective: To evaluate the curative effect of moderate and highly malignant NHL treated by combined Fu Zheng Kang Ai preparation and CHOP plan.
Method: 40 three or four stage's patients of invasion NHL according to investigative condition were selected, which were treated by the tumor department in the in-patient department of my school's affiliated hospital from June, 2005 to June, 2007, and to divide these patients into the union treatment group and the pure chemotherapy group according to the different treatment, each group was 20 cases. Both groups accepted 2 periods chemotherapy of CHOP plan, in which the union chemotherapy group took decoction of Tian Jing Bu Yuan preparation before 5 days of the CHOP plan chemotherapy starting, three times a day, 100ml one time, and to take the decoction persisted continuously. After chemotherapy completed, to observe the improvement of the quality situation and the poisonous side reaction of the two groups.
Results: The union treatment group had statistics significance on the aspect of improvement of the pathogenetic condition and the traditional Chinese's symptom compared to the pure chemotherapy group. (P<0.05)
Conclusion: Associated CHOP plan and Tian Jing Bu Yuan preparation which was combined based on the Chinese medicine's theory of Bu Pi Yi Shen, Tian Jing Bu Yuan to treat NHL, can improve the patient condition, stabilize the focus of infection, and enhance the patient's quality of life, as well had the remarkable curative effect, which was worth to clinical promoting.
方法:选取我校附院肿瘤科2005年6月至2007年6月住院部所收治的40例符合研究条件的各期NHL患者,依据其接受的治疗不同分为联合治疗组和单纯化疗组,各20例。两组均接受了2周期的CHOP化疗,其中联合化疗组于CHOP方案化疗前5天开始服用扶正抗癌150ml/tid,并一直坚持持续服药。观察两组化疗结束时,患者生活质量改善情况及毒副反应。
结果:联合治疗组和单纯化疗组相比其中医证候及其病情改善均有统计学意义(P＜0.05)。
结论:依据中医补脾益肾,填精补元理论配伍的扶正抗癌方联合CHOP方案治疗NHL,能够改善患者病情,稳定病灶,提高患者生活质量,且有显著疗效,值得临床推广。
Objective: To evaluate the curative effect of moderate and highly malignant NHL treated by combined Fu Zheng Kang Ai preparation and CHOP plan.
Method: 40 three or four stage's patients of invasion NHL according to investigative condition were selected, which were treated by the tumor department in the in-patient department of my school's affiliated hospital from June, 2005 to June, 2007, and to divide these patients into the union treatment group and the pure chemotherapy group according to the different treatment, each group was 20 cases. Both groups accepted 2 periods chemotherapy of CHOP plan, in which the union chemotherapy group took decoction of Tian Jing Bu Yuan preparation before 5 days of the CHOP plan chemotherapy starting, three times a day, 100ml one time, and to take the decoction persisted continuously. After chemotherapy completed, to observe the improvement of the quality situation and the poisonous side reaction of the two groups.
Results: The union treatment group had statistics significance on the aspect of improvement of the pathogenetic condition and the traditional Chinese's symptom compared to the pure chemotherapy group. (P<0.05)
Conclusion: Associated CHOP plan and Tian Jing Bu Yuan preparation which was combined based on the Chinese medicine's theory of Bu Pi Yi Shen, Tian Jing Bu Yuan to treat NHL, can improve the patient condition, stabilize the focus of infection, and enhance the patient's quality of life, as well had the remarkable curative effect, which was worth to clinical promoting.
引文
(1) 花宝金,冯利肿瘤的中医药多靶点治疗癌症进展杂志,2004,2:441-445.
(2) 杨镇主编 肿瘤免疫学武汉:湖北科学技术出版社,1998:186
(3) 王毓銮,米振国等现代非霍奇金淋巴瘤学 第一版(M).北京:人民军医出版社,2003:222
(4) 秦凤展,陈振东,樊青霞肿瘤内科治疗学(M) 北京:人民军医出版社,2004:372-373
(5) 李万峥 谢守勇 中西医结合治疗化疗中常见的骨髓抑制反应四川中医2005年第23卷第9期18
(6) 郑红刚,朴炳奎 浅议放化疗毒副作用的中医病因中国中医基础医学杂志2007年第13卷第10期:751
(7) 张明珠,何广元,朱红.恶性肿瘤患者放化疗后白细胞参数变化的探讨[J].现代肿瘤医学,2005:13(3):335-337
(8) 高喜源,李俊英中药对放疗毒副作用的临床观察[J].中华实用中西医杂志,2004:17(6):902-903
(9) 李仪奎 现代中医药应用与研究大全第2卷中药(M)上海:上海中医药大学出版社,1995.28.
(10) 中华人民共和国药政管理局.现代实用本草.第1版.北京:人民卫生出版社,1997:248.
(11) 周则卫,沈秀,吴小霞等 天然蛇床子素的抗肿瘤活性实验研究癌变畸变突变论著07年3月第19卷第二期0119-0121
(12) 王谦,张玲,毛海婷等 中药淫羊藿苷逆转肝癌HepG2.2.15细胞恶性表型及诱导分化研究世界华人消化杂志2007年7月8日:15(19):2087-2092 ISSN 1009-3079 CN 14-1260/R.
(13) 吴琼,程小卫,雷光青等 仙茅苷对自由基的清除作用 中国现代应用药学杂志2007年2月第24卷第1期6-9
(14) FISHER G J,WANG Z Q,DATTA S C,et al.Pathophysiology of premature skinaging induced by ultraviolet light[J].NenglJmed,1997,337:1419-1428.
(15) 闫晓光.补骨脂素类抗肿瘤作用的光敏特性研究[J].国外医学肿瘤学分册,1999,4(26):85-89.
(16) 李冬云,陈信义,刘瑞娟.单味中药成分逆转白血病多药耐药基础研究评述[J].中国中医药信息杂志,2004,11(11):951-954.
(17) 季宇彬.抗癌中药药理与应用[M].哈尔滨:黑龙江科学技术出版社,2004:870-871
(18) Cullen MH,Billinghsm LJ.Woodroffe CM,etal.Metomycin,ifosfamide and eisplatin in unresectable non-small-cell lung cancer:effects on survival and quality of life(J).Clin Oncol.1999,10:3188-3194.
(1) 叶乃瑶,兰海涛非霍奇金淋巴瘤治疗进展 实用医院临床杂志2006年1月第3卷第1期13
(2) 徐钢 EB病毒与恶性淋巴瘤的关系 国外医学 胜利病理科学与临床分册1995 15(4)
(3) 周小鸽 张颈松 严庆汉等 B细胞淋巴瘤与EB病毒关系的观察 CHin J Pathol 1996 25 1
(4) 管俊,姜扬文,殷 杰等ACES方案治疗难治性或复发性非霍奇金淋巴瘤的疗效观察 肿瘤基础与临床2007年10月第20卷第5期407
(5) Mey UJ,Orlopp KS,FliegerD,et al.Dexamethasone,high2dose cytarabine and cisp latin in combination with rituximab as salvage treatment for patients with relap sed or refractory aggressive non-Hodgkins lymphoma[J].Cancer Invest,2006,24(6):593-600.
(6) Velasquez WS,Cabanillas F,Salvador P,et al.Effective salvage therapy for lymphoma with cisp latin in combination with highdose Ara-C and dexamethasone(DHAP)[J].Blood,1988,71(1),117-122
(7) 欧阳学农,王文武,彭永海GMEP方案治疗难治性或复发性非霍奇金淋巴瘤的近期疗效报告福州总医院学报2006年9月第12卷第3期 131
(8) Zinzani PL,Tani M,Stefoni V et al.Efficacy of vinorelbine,epirubicin and prednisone combination regimen in pretreated,elderly patients with aggressive non-Hodgkins lymphoma.Haematologica,2001,86(3):287
(9) Koc H,Arslan O,Gurman G,et al.Useof high-dose chemotherapy plus granulocyte colony-stimulating facto for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.Acta Haematol,1997,98(3);136
(10) 罗盛,沈志坚,胡旭东M INE-ESHAP方案治疗复发或难治侵袭性非霍奇金淋巴瘤的观察 中国医师进修杂志2007年7月5日第30卷第7期内科版Chin J PostgradMed,July 5 th 2007,Vol.30,No.7A
(11)黄勇,秦叔逵,王琳,杨宁蓉等 三氧化二砷注射液治疗复发难治性恶性淋巴瘤的临床研究 临床肿瘤学杂志2007年8月第12卷第8期 Chinese ClinicalOncology,Aug.2007,Vol.12,No.8
(12) Chen D,Chan R,Waxman S,et al.Buthionine sulfoximine enhancement of arsenic trioxide2induced apop tosis in leukemia and lymphoma cells ismediated via activation of c-Jun NH22-terminal kinase and up2regulation of death recep tors[J].Cancer Res,2006,66(23):11416-11423.
(13) Zhou L,J ing Y,StybloM,et al.Glutathione-S-transferase p i inhibits As203 induced apop tosis in lymphoma cells:involvement of hydrogen peroxide catabolism[J].Blood,2005,105(3):1198-1203.
(14) 何冬梅,张洹,刘革修等 三氧化二砷诱导Raji细胞凋亡过程中端粒酶活性和hTERT、Bcl-2基因表达的研究[J].中国病理生理杂志,2005,21(7):1422-1423,1430
(15) 李贺,熊茂明,孟翔凌等 三氧化二砷逆转肝癌细胞株HepG2/ADM多药耐药的作用[J].世界华人消化杂志,2006,14(27):2691-2694.
(16) 王涛,马梁明 三氧化二砷对肿瘤多药耐药的作用及其机制[J].国外医学输血及血液学分册,2006,29(3):253-256.
(17) Hainsworth JD.Rituximab as first2line and maintenance therapy for patients with indolent non Hodgkinps lymphoma:interim follow up of amulticenter phase Ⅱ trial[J].Semin Oncol,2002,29(1):25-9.
(18) Colombat P,Salles G,Brousse N,et al.Rituximab(anti-CD-O monoclonal antibody) as single first21ine therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation[J].Blood,2001,97(1):101-6.
(19) Czuczman AJ,Grillo Lopez CA,White,et al.Treatment of patients with low grade B cell lymphoma with the combination of chimeric anti CD20monoclonal antibody and CHOP chemotherapy[J].Clin Oncol,1999,17(1):268-76.
(20) Howard OM,Gribben JG,NeubergDS,et al.Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma:molecular complete responses are not predictive of progression free survival[J].J Clin Oncol,2002,20(5):1288-94.
(21) Coiffier B,Haioun C,Ketterer N,et al.Rituximab(anti CD20mon-oclonal antibody) for the treatment of patients with relap sing orrefractory aggressive lymphoma:a multi center phase Ⅱ study[J].Blood,1998,92(6):1927-32.
(22) CoiffierB,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab comparedwith CHOP alone in elderly patients with diffuse large B cell lymphoma[J].N Engl J Med,2002,346(4):235-42.
(23) Vose JM,Link BK,GrossbardML,et al.Phase Ⅱ study of Rituximab in combination with chop chemotherapy in patientswith p reviously untreated aggressive non2Hodgkinps lymphoma[J].J Clin Oncol,2001,19(2):389-97.
(24) Feugier P,Van Hoof A,Sebban C,et al.Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe dpEtude des Lymphomes de lpAdulte [J].J Clin Oncol.2005,23(18):4117-26.
(25) MagniM,Di NicolaS,Devizzi L,et al.Successful in vivo purging of CD34 containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and ritaximab infusion[J].Blood,2000,96(3):864-9.
(26) Van Besien KW,de LimaM,Giralt SA,et al.Management of lymphoma recurrence after allogeneic transp lantation:the relevance of graft-versus-lymphoma effects[J].Bone Marrow Transplant,1997,19(10):977-82.
(27) 董志高,朱雄鹏 非霍奇金淋巴瘤的生物学治疗进展 《中国老年保健医学》杂志[J]2007年第5卷第1期27
(28) Hardingham JB,Kotasek D,Sage RElet allSignificance 0f molecular marker-positive cell after autologous peripheral-blood stem-cell:transplantation for non-Hodgkin's lymphomal[J]J Clin Oncol,1995,13(5):1073
(29) Mineishi S.Future directions of mini2transp lant[J].Nippon Rinsho,2003,61(9):1655-7.
(30) 陈幸华,张曦,高蕾大剂量化疗自体外周血干细胞移植生物治疗序贯疗法对67例非霍奇金淋巴瘤的疗效观察中国实用内科杂志[J]2007年10月第27卷第20期1605
(31) Lenz G,DreylingM,Hoster E.Immunochemotherapywith rituximab and cyclophosphamide,doxorubicin,vincristine,and pred-nisone significantly imp roves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study.Group(GLSG)[J].J Clin Oncol,2005,23(9):1984-1992.
(32) Romaguera JE,Fayad L,RodriguezMA.High rate of durable re-missions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternatingwith ritux-imab plus high-dose methotrexate and cytarabine[J].J Clin On-col,2005,23(28):7013-7023.
(33) FischbachW,Goebeler KME,Dragosics B.Long term outcome of patientswith gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue(MALT) following exclusive Helico-bacter pylori eradication therapy:experience from a large p rospec-tive series[J].Gut,2004,53(1):34-37.
(34) 于燕霞,石远凯几种较少见类型非霍奇金淋巴瘤的治疗进展 临床肿瘤学杂志2007年6月第12卷第6期[J]Chinese ClinicalOncology,Jun.2007,Vol.12,No.6
(35) Thomas DA,OpBrien S,Cortes J.Outcome with the hyper CVAD regimens in lymphoblastic lymphoma[J].Blood,2004,104(6):1624-1630.
(36) Gallamini A,Stelitano C,Calvi-R.Peripheral T-cell lymphoma unspecified(PTCL-U):a new p rognostic model from a retrospective multicentric clinical study[J].Blood,2004,103(7):2474-2479.
(37) Hart,D1N1,and G1R1Hill119991Dendritic cell immunotherapy for cancer:application to low-grade lymphoma and multiple myelomalImmunollCell1Biol177:451.
(38) Rogalski C,Dummer R,Burg GlImmunomodulators in the treatment of cutaneous lymphoma[J]1J Eur Acade Dermatol Venereol,1999,13(2):83.
(39) Nicolas Mounier,Josette Brfere,Christian GisselbrechtlRituximab plus CHOP(R-CHOP) overcOmes bcl-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma(DLBCL)lBlood12003,101:4279-4284
(40) 刘伟胜,徐凯 中医临床诊治肿瘤科专病[M]447
(41) Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas.Blood 2003,101(2):391-398
(42) Emmanouilides C.Radioimmunotherapy for non-Hodgkin s lymphoma.Semin Oncol,2003,30(4):531-544
(43) Wanger HN,Wiseman GA,Marcus CS,et al.Administration guide-lines for radioimmunotherapy of non-Hodgkin s lymphoma with(90) Y-labeled anti-CD20 monoclonal antibody.J Nucl Med,2002,43(2);267-272.
(44) Witig TE,White CA,Wiseman GA,et al.Phase Ⅰ/Ⅱ trial of IDEC-Y2B8radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.J Clin Oncol,1999,17(12):3739-3803
(45) Gordan Li,Molina A,Witzig TE,et al.Durable responses after ibritumomab tiuxetan radioimmunotherapyfor CD20(+) B-cell non-Hodgkin's lymphoma:long-term,follow-up of a phase 1/2 study.Blood,2004,103(12):4429-4431.
(46) 周岱翰 恶性淋巴瘤的中医治疗 新中医,1987,(10):25
(47) 蔡明明,吴燕波等综合治疗恶性淋巴瘤55例临床观察.江苏中医,1994,15(4):5
(48) 王兆麟 中西医结合治疗恶性淋巴瘤28例疗效观察.江西中医药,1997,28(8):46
(49) 罗秀素,沈一平等 中西医结合治疗恶性淋巴瘤34例疗效观察.江西中医药,1998,29(3):44
(50) 谢鸣主编 中医方剂现代研究,上册.北京:学苑出版社,1997.558,593,1060
(51) 张玉五,薛颖,张秉乾 丹参对恶性淋巴瘤患者高血浆纤维蛋白原的影响.中西医结合杂志。1988,8(10):607
(52) 赵长琦,许有玲主编 抗肿瘤植物药及其有效成份.北京:中国中医药出版社,1997.45
(53) 钱伯文主编 抗癌中药的临床应用.上海:上海翻译出版公司,1987.50
(54) 中国人民解放军后勤卫生部.中国药用海洋生物.上海:上海人民出版社,1977.19
(55) 国家中医药管理局《中华草本》编委令 中华草本.上海:上海科学技术出版社,1998.339,341,1180
(56) 伍文俊 贞芪扶正冲剂治疗58例恶性肿瘤患者临床疗效观察.四川中医.1989,(8):25
(2) 杨镇主编 肿瘤免疫学武汉:湖北科学技术出版社,1998:186
(3) 王毓銮,米振国等现代非霍奇金淋巴瘤学 第一版(M).北京:人民军医出版社,2003:222
(4) 秦凤展,陈振东,樊青霞肿瘤内科治疗学(M) 北京:人民军医出版社,2004:372-373
(5) 李万峥 谢守勇 中西医结合治疗化疗中常见的骨髓抑制反应四川中医2005年第23卷第9期18
(6) 郑红刚,朴炳奎 浅议放化疗毒副作用的中医病因中国中医基础医学杂志2007年第13卷第10期:751
(7) 张明珠,何广元,朱红.恶性肿瘤患者放化疗后白细胞参数变化的探讨[J].现代肿瘤医学,2005:13(3):335-337
(8) 高喜源,李俊英中药对放疗毒副作用的临床观察[J].中华实用中西医杂志,2004:17(6):902-903
(9) 李仪奎 现代中医药应用与研究大全第2卷中药(M)上海:上海中医药大学出版社,1995.28.
(10) 中华人民共和国药政管理局.现代实用本草.第1版.北京:人民卫生出版社,1997:248.
(11) 周则卫,沈秀,吴小霞等 天然蛇床子素的抗肿瘤活性实验研究癌变畸变突变论著07年3月第19卷第二期0119-0121
(12) 王谦,张玲,毛海婷等 中药淫羊藿苷逆转肝癌HepG2.2.15细胞恶性表型及诱导分化研究世界华人消化杂志2007年7月8日:15(19):2087-2092 ISSN 1009-3079 CN 14-1260/R.
(13) 吴琼,程小卫,雷光青等 仙茅苷对自由基的清除作用 中国现代应用药学杂志2007年2月第24卷第1期6-9
(14) FISHER G J,WANG Z Q,DATTA S C,et al.Pathophysiology of premature skinaging induced by ultraviolet light[J].NenglJmed,1997,337:1419-1428.
(15) 闫晓光.补骨脂素类抗肿瘤作用的光敏特性研究[J].国外医学肿瘤学分册,1999,4(26):85-89.
(16) 李冬云,陈信义,刘瑞娟.单味中药成分逆转白血病多药耐药基础研究评述[J].中国中医药信息杂志,2004,11(11):951-954.
(17) 季宇彬.抗癌中药药理与应用[M].哈尔滨:黑龙江科学技术出版社,2004:870-871
(18) Cullen MH,Billinghsm LJ.Woodroffe CM,etal.Metomycin,ifosfamide and eisplatin in unresectable non-small-cell lung cancer:effects on survival and quality of life(J).Clin Oncol.1999,10:3188-3194.
(1) 叶乃瑶,兰海涛非霍奇金淋巴瘤治疗进展 实用医院临床杂志2006年1月第3卷第1期13
(2) 徐钢 EB病毒与恶性淋巴瘤的关系 国外医学 胜利病理科学与临床分册1995 15(4)
(3) 周小鸽 张颈松 严庆汉等 B细胞淋巴瘤与EB病毒关系的观察 CHin J Pathol 1996 25 1
(4) 管俊,姜扬文,殷 杰等ACES方案治疗难治性或复发性非霍奇金淋巴瘤的疗效观察 肿瘤基础与临床2007年10月第20卷第5期407
(5) Mey UJ,Orlopp KS,FliegerD,et al.Dexamethasone,high2dose cytarabine and cisp latin in combination with rituximab as salvage treatment for patients with relap sed or refractory aggressive non-Hodgkins lymphoma[J].Cancer Invest,2006,24(6):593-600.
(6) Velasquez WS,Cabanillas F,Salvador P,et al.Effective salvage therapy for lymphoma with cisp latin in combination with highdose Ara-C and dexamethasone(DHAP)[J].Blood,1988,71(1),117-122
(7) 欧阳学农,王文武,彭永海GMEP方案治疗难治性或复发性非霍奇金淋巴瘤的近期疗效报告福州总医院学报2006年9月第12卷第3期 131
(8) Zinzani PL,Tani M,Stefoni V et al.Efficacy of vinorelbine,epirubicin and prednisone combination regimen in pretreated,elderly patients with aggressive non-Hodgkins lymphoma.Haematologica,2001,86(3):287
(9) Koc H,Arslan O,Gurman G,et al.Useof high-dose chemotherapy plus granulocyte colony-stimulating facto for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.Acta Haematol,1997,98(3);136
(10) 罗盛,沈志坚,胡旭东M INE-ESHAP方案治疗复发或难治侵袭性非霍奇金淋巴瘤的观察 中国医师进修杂志2007年7月5日第30卷第7期内科版Chin J PostgradMed,July 5 th 2007,Vol.30,No.7A
(11)黄勇,秦叔逵,王琳,杨宁蓉等 三氧化二砷注射液治疗复发难治性恶性淋巴瘤的临床研究 临床肿瘤学杂志2007年8月第12卷第8期 Chinese ClinicalOncology,Aug.2007,Vol.12,No.8
(12) Chen D,Chan R,Waxman S,et al.Buthionine sulfoximine enhancement of arsenic trioxide2induced apop tosis in leukemia and lymphoma cells ismediated via activation of c-Jun NH22-terminal kinase and up2regulation of death recep tors[J].Cancer Res,2006,66(23):11416-11423.
(13) Zhou L,J ing Y,StybloM,et al.Glutathione-S-transferase p i inhibits As203 induced apop tosis in lymphoma cells:involvement of hydrogen peroxide catabolism[J].Blood,2005,105(3):1198-1203.
(14) 何冬梅,张洹,刘革修等 三氧化二砷诱导Raji细胞凋亡过程中端粒酶活性和hTERT、Bcl-2基因表达的研究[J].中国病理生理杂志,2005,21(7):1422-1423,1430
(15) 李贺,熊茂明,孟翔凌等 三氧化二砷逆转肝癌细胞株HepG2/ADM多药耐药的作用[J].世界华人消化杂志,2006,14(27):2691-2694.
(16) 王涛,马梁明 三氧化二砷对肿瘤多药耐药的作用及其机制[J].国外医学输血及血液学分册,2006,29(3):253-256.
(17) Hainsworth JD.Rituximab as first2line and maintenance therapy for patients with indolent non Hodgkinps lymphoma:interim follow up of amulticenter phase Ⅱ trial[J].Semin Oncol,2002,29(1):25-9.
(18) Colombat P,Salles G,Brousse N,et al.Rituximab(anti-CD-O monoclonal antibody) as single first21ine therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation[J].Blood,2001,97(1):101-6.
(19) Czuczman AJ,Grillo Lopez CA,White,et al.Treatment of patients with low grade B cell lymphoma with the combination of chimeric anti CD20monoclonal antibody and CHOP chemotherapy[J].Clin Oncol,1999,17(1):268-76.
(20) Howard OM,Gribben JG,NeubergDS,et al.Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma:molecular complete responses are not predictive of progression free survival[J].J Clin Oncol,2002,20(5):1288-94.
(21) Coiffier B,Haioun C,Ketterer N,et al.Rituximab(anti CD20mon-oclonal antibody) for the treatment of patients with relap sing orrefractory aggressive lymphoma:a multi center phase Ⅱ study[J].Blood,1998,92(6):1927-32.
(22) CoiffierB,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab comparedwith CHOP alone in elderly patients with diffuse large B cell lymphoma[J].N Engl J Med,2002,346(4):235-42.
(23) Vose JM,Link BK,GrossbardML,et al.Phase Ⅱ study of Rituximab in combination with chop chemotherapy in patientswith p reviously untreated aggressive non2Hodgkinps lymphoma[J].J Clin Oncol,2001,19(2):389-97.
(24) Feugier P,Van Hoof A,Sebban C,et al.Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe dpEtude des Lymphomes de lpAdulte [J].J Clin Oncol.2005,23(18):4117-26.
(25) MagniM,Di NicolaS,Devizzi L,et al.Successful in vivo purging of CD34 containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and ritaximab infusion[J].Blood,2000,96(3):864-9.
(26) Van Besien KW,de LimaM,Giralt SA,et al.Management of lymphoma recurrence after allogeneic transp lantation:the relevance of graft-versus-lymphoma effects[J].Bone Marrow Transplant,1997,19(10):977-82.
(27) 董志高,朱雄鹏 非霍奇金淋巴瘤的生物学治疗进展 《中国老年保健医学》杂志[J]2007年第5卷第1期27
(28) Hardingham JB,Kotasek D,Sage RElet allSignificance 0f molecular marker-positive cell after autologous peripheral-blood stem-cell:transplantation for non-Hodgkin's lymphomal[J]J Clin Oncol,1995,13(5):1073
(29) Mineishi S.Future directions of mini2transp lant[J].Nippon Rinsho,2003,61(9):1655-7.
(30) 陈幸华,张曦,高蕾大剂量化疗自体外周血干细胞移植生物治疗序贯疗法对67例非霍奇金淋巴瘤的疗效观察中国实用内科杂志[J]2007年10月第27卷第20期1605
(31) Lenz G,DreylingM,Hoster E.Immunochemotherapywith rituximab and cyclophosphamide,doxorubicin,vincristine,and pred-nisone significantly imp roves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study.Group(GLSG)[J].J Clin Oncol,2005,23(9):1984-1992.
(32) Romaguera JE,Fayad L,RodriguezMA.High rate of durable re-missions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternatingwith ritux-imab plus high-dose methotrexate and cytarabine[J].J Clin On-col,2005,23(28):7013-7023.
(33) FischbachW,Goebeler KME,Dragosics B.Long term outcome of patientswith gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue(MALT) following exclusive Helico-bacter pylori eradication therapy:experience from a large p rospec-tive series[J].Gut,2004,53(1):34-37.
(34) 于燕霞,石远凯几种较少见类型非霍奇金淋巴瘤的治疗进展 临床肿瘤学杂志2007年6月第12卷第6期[J]Chinese ClinicalOncology,Jun.2007,Vol.12,No.6
(35) Thomas DA,OpBrien S,Cortes J.Outcome with the hyper CVAD regimens in lymphoblastic lymphoma[J].Blood,2004,104(6):1624-1630.
(36) Gallamini A,Stelitano C,Calvi-R.Peripheral T-cell lymphoma unspecified(PTCL-U):a new p rognostic model from a retrospective multicentric clinical study[J].Blood,2004,103(7):2474-2479.
(37) Hart,D1N1,and G1R1Hill119991Dendritic cell immunotherapy for cancer:application to low-grade lymphoma and multiple myelomalImmunollCell1Biol177:451.
(38) Rogalski C,Dummer R,Burg GlImmunomodulators in the treatment of cutaneous lymphoma[J]1J Eur Acade Dermatol Venereol,1999,13(2):83.
(39) Nicolas Mounier,Josette Brfere,Christian GisselbrechtlRituximab plus CHOP(R-CHOP) overcOmes bcl-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma(DLBCL)lBlood12003,101:4279-4284
(40) 刘伟胜,徐凯 中医临床诊治肿瘤科专病[M]447
(41) Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas.Blood 2003,101(2):391-398
(42) Emmanouilides C.Radioimmunotherapy for non-Hodgkin s lymphoma.Semin Oncol,2003,30(4):531-544
(43) Wanger HN,Wiseman GA,Marcus CS,et al.Administration guide-lines for radioimmunotherapy of non-Hodgkin s lymphoma with(90) Y-labeled anti-CD20 monoclonal antibody.J Nucl Med,2002,43(2);267-272.
(44) Witig TE,White CA,Wiseman GA,et al.Phase Ⅰ/Ⅱ trial of IDEC-Y2B8radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.J Clin Oncol,1999,17(12):3739-3803
(45) Gordan Li,Molina A,Witzig TE,et al.Durable responses after ibritumomab tiuxetan radioimmunotherapyfor CD20(+) B-cell non-Hodgkin's lymphoma:long-term,follow-up of a phase 1/2 study.Blood,2004,103(12):4429-4431.
(46) 周岱翰 恶性淋巴瘤的中医治疗 新中医,1987,(10):25
(47) 蔡明明,吴燕波等综合治疗恶性淋巴瘤55例临床观察.江苏中医,1994,15(4):5
(48) 王兆麟 中西医结合治疗恶性淋巴瘤28例疗效观察.江西中医药,1997,28(8):46
(49) 罗秀素,沈一平等 中西医结合治疗恶性淋巴瘤34例疗效观察.江西中医药,1998,29(3):44
(50) 谢鸣主编 中医方剂现代研究,上册.北京:学苑出版社,1997.558,593,1060
(51) 张玉五,薛颖,张秉乾 丹参对恶性淋巴瘤患者高血浆纤维蛋白原的影响.中西医结合杂志。1988,8(10):607
(52) 赵长琦,许有玲主编 抗肿瘤植物药及其有效成份.北京:中国中医药出版社,1997.45
(53) 钱伯文主编 抗癌中药的临床应用.上海:上海翻译出版公司,1987.50
(54) 中国人民解放军后勤卫生部.中国药用海洋生物.上海:上海人民出版社,1977.19
(55) 国家中医药管理局《中华草本》编委令 中华草本.上海:上海科学技术出版社,1998.339,341,1180
(56) 伍文俊 贞芪扶正冲剂治疗58例恶性肿瘤患者临床疗效观察.四川中医.1989,(8):25